Aspen sells Arixtra to Mylan after year-end GSK deal
This article was originally published in Scrip
Executive Summary
Mylan will pay $300m to buy Arixtra (fondaparinux sodium) and the thrombosis drug's authorized generic from Aspen Global, which has had possession of the assets only since the end of 2013 when the African company's acquisition of two GlaxoSmithKline drugs closed.